HPV-RNA - detection of mRNA of E6 and E7 oncogenes -met. PCR -genetic testing

• The test material is a cervical swab.

  The test should not be performed:
  - during menstruation,
  - during treatment with antibiotics, steroids,
  - during treatment with vaginal preparations (globules, creams),
  - when irrigations are used,
  - within 48 hours after the last sexual intercourse.
  If treatment was used, a 3-5 day break is recommended between the end of treatment,
  and the performance of the test.
  Moisturizers, intimate hygiene products, contraceptive gels
  (with the exception of Advantage - S ® Bioadhesive Contraceptive Gel) do not interfere with the test.

Próbki przyniesione z zewnątrz nie są przyjmowane do badania.
Nie wykonujemy badania u mężczyzn.
W przypadku mężczyzn należy wybrać test wykrywający DNA wirusa HPV:
HPV- BADANIE GENETYCZNE (14 GENOTYPÓW) lub HPV- BADANIE GENETYCZNE (16 GENOTYPÓW) w zalezności od stanu klinicznego. Test HPV 16 genotypów jest przydatny przy podejrzeniu kłykcin kończystych.

The test detects mRNA transcripts of high-oncogenic HPV genotypes ( 16,18, 31,33,45). This test is recommended by the Gynecological Society and recommended by the Central Coordinating Center of the Population Prevention Program

and Early Detection of Cervical Cancer for patients who have an abnormal cytology smear result.

The HPV mRNA test is much more sensitive than the basic HPV test, which we also offer, because it detects viral activity leading to the development of cancer, rather than the presence of the virus itself.

INFO EXTENDED

Testing for HPV infection (HPV mRNA) - HIGH RISK ONCOGENIC

enables detection of active oncogenes E6 and E7 of high-risk oncogenic HPV virus types 16, 18, 31, 33, 45. High-risk HPV viruses are considered the main factor in the development of cervical cancer (their presence is found in 97-99.7% of cases of cervical cancer).

Oncogenes E6 and E7 of HPV, are an important factor in the formation of changes in the cells of the cervix, which can lead to the development of cervical cancer. Their synthesis occurs mainly in the case of persistent high-risk HPV infections (in about 80% of cases of HPV infections, the infection is fought by the woman's immune system). Therefore, a positive result obtained with the NucliSENS EasyQ HPV test more accurately indicates an increased likelihood of developing invasive cervical cancer than the more commonly available HPV DNA tests.

The necessity of the test should be decided by a gynecologist.

It is recommended for women of all ages, including those patients who have previously been diagnosed with oncogenic HPV DNA

These tests use advanced technology with the latest generation of reagents and equipment, certified by CE-IUD for clinical use. Strict quality control systems must be followed.

ADDITIONAL INFORMATION

Most women fight the virus before it causes unwanted effects. Abnormal cells develop in the cervical epithelium only if the infection with oncogenic HPV types does not pass. In most cases, the body of a healthy, young woman (under 30 years of age) will destroy the virus. In such a situation, all features of the infection - including abnormal cervical cells - will disappear spontaneously after 6-24 months. However, sometimes the infection with the oncogenic type of HPV takes a persistent form, in which the virus produces in excess the so-called EB/E7 oncoprotein mRNA directly responsible for triggering cancerous processes in the cervix. The result is the formation, after a certain period of time (usually several months - several years), of precancerous changes in the cells of the epithelium of the cervix defined as dysplasia, CIN or SIL. Untreated advanced dysplasia (so-called CIN III or HSIL) can lead to the development of the disease .Prevention, early detection and treatment of dysplasia caused by oncogenic HPV viruses protects most women from cervical cancer.

It should be noted that due to the high prevalence (up to 25%) of HPV infections in younger women under 30 years of age, HPV tests based on DNA analysis have less specificity and limited applicability, because if performed once, they cannot distinguish whether the infection is transient or persistent - associated with the risk of developing dysplasia and cancer. In this age group, HPV DNA testing is helpful for inconclusive cytology (ASC-US) and low-grade dysplasia (CIN1 or LSIL), as well as for monitoring treatment, such as after surgical conization. For prognostic purposes, HPV DNA tests should, in principle, be used only in women over the age of 30.

New-generation tests based on HPV mRNA analysis, on the other hand, can be used in women of all ages and have the highest diagnostic and prognostic value - the so-called positive predictive value (PPV) of these tests is at least twice as high as that of viral DNA analysis.

Enter a one-time code:Show
An invalid code has been entered. Please try again.